TRAX director exercises 6,030 RSUs into shares

First Tracks Biotherapeutics director Magda Marquet exercised restricted stock units into common shares.

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Magda Marquet exercised restricted stock units into common shares. On June 15, 2026, she converted 6,030 restricted stock units into 6,030 shares of common stock for no cash consideration, reflecting compensation rather than a market purchase or sale.

Following the transaction, she directly owns 15,960 shares of common stock. The RSU award vested 100% on June 15, 2026, contingent on her continued service to the company through that date.

Insider Trade Summary

6,030 shares exercised/converted

Exercise 2 txns

Insider Marquet Magda

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	$0.00
Exercise	Common Stock	6,030	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 15,960 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs exercised: 6,030 shares Shares owned after transaction: 15,960 shares Exercise/settlement price: $0.00 per share +1 more

4 metrics

RSUs exercised 6,030 shares Restricted stock units converted to common stock on June 15, 2026

Shares owned after transaction 15,960 shares Common stock directly held by Magda Marquet after June 15, 2026

Exercise/settlement price $0.00 per share RSUs settled for no cash consideration

Exercise events 1 transaction Derivative exercise/conversion transactions in this Form 4

Key Terms

Restricted Stock Unit, derivative security, contingent right

3 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Magda Marquet report at First Tracks Biotherapeutics (TRAX)?

Magda Marquet reported exercising 6,030 restricted stock units into 6,030 shares of common stock. The transaction reflects settlement of equity compensation, not an open-market trade, and occurred on June 15, 2026, according to the Form 4 data.

Did Magda Marquet buy or sell First Tracks Biotherapeutics (TRAX) shares on the market?

She did not buy or sell shares on the open market. Instead, 6,030 restricted stock units converted into common stock for no cash consideration, representing equity compensation vesting rather than a discretionary market transaction.

How many First Tracks Biotherapeutics (TRAX) shares does Magda Marquet hold after this filing?

After the June 15, 2026 transaction, Magda Marquet directly holds 15,960 shares of First Tracks Biotherapeutics common stock. This total reflects the addition of 6,030 shares received from the restricted stock unit settlement reported.

What are the key details of the restricted stock units in this TRAX Form 4?

Each restricted stock unit represents a contingent right to receive one share of common stock at settlement for no consideration. The award vested 100% on June 15, 2026, subject to Magda Marquet’s continued service with First Tracks Biotherapeutics through that date.

Is Magda Marquet’s Form 4 transaction at TRAX a routine compensation event?

Yes. The Form 4 shows 6,030 restricted stock units vesting and converting into common shares for no cash payment. This indicates a routine equity compensation vesting event, with no simultaneous reported sale of the newly issued shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marquet Magda

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		6,030	A	$0(1)	15,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/15/2026		M			6,030	(2)	(2)	Common Stock	6,030	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)